Matthew Foehr
Equibles does not estimate personal net worth.
About Matthew Foehr
Earlier roles on record: COO at Ligand Pharmaceuticals Inc (LGND) until November 1, 2022. Ligand Pharmaceuticals Inc reported in an 8-K filed November 4, 2022 that Matthew Foehr resigned as President and Chief Operating Officer, effective November 1, 2022. The proxy statement of Ligand Pharmaceuticals Inc reports total compensation of $4,007,766 for Matthew Foehr in fiscal 2022, including a base salary of $451,057. Disclosed compensation is on record for 6 fiscal years. Matthew Foehr has spoken on 4 earnings calls across 1 company, most recently for Ligand Pharmaceuticals Inc on August 8, 2022. The companies whose calls Matthew Foehr spoke on are classified in the Healthcare sector.
“on November 1, 2022, in connection with the Separation, Matthew Foehr and Charles Berkman resigned as Ligand's President and Chief Operating Officer and Senior Vice President, General Counsel and Secretary, respectively.”
Matthew Foehr on recent calls
“I'm going to focus my comments this afternoon on our OmniAb platform as we continue to prepare for the business to become an independent publicly traded company in the fourth quarter.”
“As John mentioned, Q2 was a very productive quarter with partner product approvals followed by recent launches, expanding relationships with existing partners, and entering into new deals with new partners.”
“This afternoon, I'm going to review the status plans in recent developments involving a couple of our core technology platforms starting with OmniAb. I'll then provide updates on certain partner programs with major events expected later this year, and also update plans for our Captisol enabled Iohexol program.”
“Now on Slide 16, our technologies and the license associated with them form the foundation of our portfolio. Our technologies enable new medicines through our licensing partnerships and ultimately help patients by meeting major unmet medical needs.”
Affiliation history
-
Start not stated–2022-11-01
-
Start not stated–2022-11-01
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Ligand Pharmaceuticals Inc (LGND) | Former President and Chief Operating Officer | $451,057 | $4,007,766 |
| 2021 | Ligand Pharmaceuticals Inc (LGND) | Former President and Chief Operating Officer | $518,933 | $5,282,204 |
| 2020 | Ligand Pharmaceuticals Inc (LGND) | Former President and Chief Operating Officer | $503,750 | $3,484,449 |
| 2019 | Ligand Pharmaceuticals Inc (LGND) | President and Chief Operating Officer | $487,500 | $4,244,909 |
| 2018 | Ligand Pharmaceuticals Inc (LGND) | President and Chief Operating Officer | $458,931 | $3,324,140 |
| 2017 | Ligand Pharmaceuticals Inc (LGND) | President and Chief Operating Officer | $442,094 | $3,458,503 |